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Abstract
Background: For improved uptake of oligonucleotide-based therapy, the oligonucleotides often are coupled to
peptides that facilitate entry into cells. To this end, novel cell-penetrating peptides (CPPs) were designed for
mediating intracellular uptake of oligonucleotide-based therapeutics. The novel peptides were based on taking
advantage of the nuclear localization properties of transcription factors in combination with a peptide that would
bind putatively to cell surfaces. It was observed that adding a glutamate peptide to the N-terminus of the nuclear
localization signal (NLS) of the Oct6 transcription factor resulted in a novel CPP with better uptake and better
nuclear colocalization than any other peptide tested.
Results: Uptake of the novel peptide Glu-Oct6 by cancer cell lines was rapid (in less than 1 hr, more than 60% of
DU-145 cells were positive for FITC), complete (by 4 hr, 99% of cells were positive for FITC), concentration-
dependent, temperature-dependent, and inhibited by sodium azide (NaN3). Substitution of Phe, Tyr, or Asn
moieties for the glutamate portion of the novel peptide resulted in abrogation of novel CPP uptake; however none
of the substituted peptides inhibited uptake of the novel CPP when coincubated with cells. Live-cell imaging and
analysis by imaging flow cytometry revealed that the novel CPP accumulated in nuclei. Finally, the novel CPP was
coupled to a carboxyfluorescein-labeled synthetic oligonucleotide, to see if the peptide could ferry a therapeutic
payload into cells.
Conclusions: These studies document the creation of a novel CPP consisting of a glutamate peptide coupled to
the N-terminus of the Oct6 NLS; the novel CPP exhibited nuclear colocalization as well as uptake by prostate and
pancreatic cancer cell lines.
Background
Experimental therapeutic approaches using oligonucleo-
tides for prostate and pancreatic cancer are actively
investigated in many laboratories, including ours [1,2].
Such inhibitors are attractive in theory but lack a practi-
cal method for delivery in the clinical setting. One pos-
sible approach to overcome this roadblock is to use
peptide-mediated transport, thereby coupling a cell-
penetrating peptide (CPP) to a therapeutic payload, such
as a peptide nucleic acid (PNA). An inherent advantage
of using CPPs is the ability to design cell specificity in
the sequence, as well as target organelle specificity
through inclusion of nuclear localization signals (NLS).
CPP-mediated can be quite efficient, allowing for rapid
and complete uptake and delivery of a PNA payload for
the treatment of HIV [3].
CPPs for delivery of therapeutic oligonucleotides have
gained attention in recent years; an excellent review
describing the major categories of CPPs was published
earlier this year [4]. CPPs for prostate cancer have been
examined in conjunction with delivery of methotrexate-
loaded liposomes [5,6], double-stranded decoys [7], and
radioactive gadolinium complexes targeted to c-myc [8].
As for pancreatic cancer, the antennepedia protein Antp
when coupled to the tumor suppressor p16 successfully
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inhibited cell growth [9], and the insulin-like growth
factor loop 1 peptide IGF1 is being tried for imaging of
early pancreatic tumors [10].
Our laboratory has been involved in STAT3 inhibition
for cancer therapy for a number of years. Previously, we
designed oligonucleotides that inhibited STAT3 expres-
sion with concomitant abrogation of STAT3 target gene
expression [1,2]. It had long been our intention to use
PNAs as therapeutic entities for STAT3, given the
superior properties of PNAs compared to oligonucleo-
tides for this purpose. PNAs bind strongly to RNA or
DNA, more strongly than antisense or RNAi, thereby
inhibiting transcription of gene(s) through the creation
of triple helices. The structure of PNAs makes them
highly resistant to nucleases and proteases [11]. Finally,
PNAs form triple helices with duplex DNA, making
them ideal candidate molecules for inhibiting transcrip-
tion factors [12]. However, PNAs need suitable CPPS
for transport into cells. And in the case of inhibiting a
transcription factor such as STAT3, nuclear colocaliza-
tion is highy desirable since the nucleus is the main seat
of transcription factor activity.
One strategy for CPP design recently examined is to
use the NLS peptides of transcription factors themselves
as CPPs. The NLS of several transcription factors have
been compared in various tumor types with varying
degrees of efficacy with regard to uptake and nuclear
localization, however sequestration in endosomes was
observed for many of the peptides tested [13]. As for
delivery of an oligonucleotide or PNA payload, one
study using CPPs consisting of cell surface ligands
linked to NLS and conjugated to peptide nucleic acids
(PNAs) found optimal efficacy under serum-free condi-
tions at 5 mM, a concentration that is not commercially
feasible due to prohibitive costs [14]. Clearly, more stu-
dies on designing and optimizing CPPs for delivery of
therapeutic oligonucleotide or PNA payloads are needed
in order to bring new therapeutic entities to the clinic.
In this paper, the creation of a novel CPP combining
the NLS of a transcription factor with another peptide
that was observed to enhance cellular uptake and
nuclear localization. By adding a glutamate-rich peptide
(EEEAA) to the N-terminus of the Oct6 transcription
factor NLS, a novel CPP was created that entered pro-
static and pancreatic cancer cell lines readily. As little as
30 nM of the FITC-labeled glutamate-rich peptide was
sufficient to stain 60-70% of the cells. Addition of a lysyl
peptide, KKK, to the glutamate-rich peptide enhanced
uptake 10-fold, and addition of the Oct6 NLS to the
glutamate-rich peptide enhanced uptake 100-fold. Com-
bining the glutamate peptide to the Oct6 NLS created a
novel peptide with better nuclear localization properties
than either the glutamate-rich peptide or the Oct6 NLS
alone. Substituting other amino acids for the glutamate
residues abrogated uptake, but coincubation of substi-
tuted peptides with the novel CPP did not inhibit
uptake, meaning that uptake of the novel CPP was
sequence-specific. Finally, when the novel peptide was
coupled to a carboxyfluorescein-labeled PNA, uptake
and nuclear localization by DU-145 cells was observed.
The rational design of CPPs using the NLS of transcrip-
tion factors for enhanced cancer cell uptake is worthy of
study for delivery of therapeutic payloads into targeted
cells.
Results
Neither a PMSA-targeted peptide nor TAT resulted in
efficient PNA uptake in DU-145 cells
Because PMSA (prostate-specific membrane antigen) is
overexpressed on most prostate cancer cells, it is an
attractive target for therapeutic delivery. Being a carbox-
yglutamate peptidase, it cleaves C-terminal Glu residues.
C-terminal peptides such as EEE have been used pre-
viously to deliver methotrexate-loaded liposomes to
prostate cancer cell lines [6]; whether a C-terminal Glu
peptide could deliver a PNA to prostate cancer cells had
not been investigated. TAT peptide, a 13-amino acid
peptide comprised of residues 48 to 60 of the human
immunodeficiency virus-1 TAT protein, has been shown
to be an efficient CPP for delivery of anti-viral oligonu-
cleotides and PNAs [3]; as is the case for EEE, it had
not been fully evaluated in most cancer lines for delivery
of PNAs. Therefore, FITC-labeled PNAs bearing either a
carboxy-terminal peptide (EEE) or an N-terminal TAT
peptide were synthesized and incubated with DU-145
cells (see Table 1 for sequences of all peptides and pep-
tide-PNAs used). Surprisingly, only about 30-50% of the
DU-145 cells were fluorescent 6 hr after start of incuba-
tion (Figure 1) and the proportion of fluorescent cells
markedly decreased over time in the case of the EEE-
labeled PNA (in the case of the TAT-labeled PNA, the
proportion of fluorescent cells remained nearly constant
over 48 hr). Based on these results, it was decided to try
other strategies for design of suitable CPPs to deliver
PNAs into cancer cell lines.
Addition of glutamate-rich peptide EEEAA to the Oct6
NLS enhanced its uptake
Uptake of peptides by live cells was compared by flow
cytometry, using either 7-amino actinomycin D (7-AAD)
or propidium iodide (PI) to exclude dead cells from ana-
lyses. Because logarithmic amplification of fluorescence
detectors were employed, the geometric mean fluores-
cence intensities (MFIs) were compared among samples.
In comparing the geometric MFIs among the peptides, it
was noted that peptides Glu-FITC and Glu-Ala-FITC (see
Table 1 for sequences) exhibited the lowest values,
whereas addition of either KKK or the Oct6 NLS (peptides
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Glu-Lys-FITC or Glu-Oct6-FITC) significantly increased
the geometric MFIs after 4 hrs incubation. These data sug-
gested the possibility that inclusion of even a minimal NLS
such as KKK could profoundly influence cellular uptake.
The influence of the Oct6 NLS peptide on uptake was
even more dramatic; however, uptake of the Oct6 NLS
alone (that is, peptide Oct6-FITC) was not nearly as great
as that of Glu-Oct6-FITC. Therefore it is possible
that both parts of the Glu-Oct6 peptide, EEEAA and the
Oct6 NLS, contributed to the enhanced property of Glu-
Oct6-FITC to function as a CPP. The kinetics of uptake
for Glu-Oct6-FITC were found to be rapid, although
saturation was not reached. Figure 2B shows that in both
DU-145 and LNCaP cells, the geometric MFI of 500 nM
at 1 hr extrapolated from the graph is nearly the same as
that measured at 4 hr (Figure 2A). In the presence of
3 mM, the geometric MFIs of the two cell lines was 1500
to 2000, and uptake was still linear. Inclusion of higher
concentrations of peptide was not feasible, due to the lim-
ited amount of peptide.
Substitution of Phe, Asn, or Tyr for Glu abrogated
peptide uptake
In order to determine if uptake of peptide Glu-Oct6-
FITC was sequence-specific, Glu residues were substi-
tuted by Phe residues (peptides Phe-Oct6-FITC,
Phe-Oct6-Dansyl, and Phe-Oct6), Asn residues (peptide
Asn-Oct6-FITC), or Tyr residues (peptides Tyr-Oct6-
FITC and Tyr-Oct6). The resulting peptides were incu-
bated at 0 to 1000 nM with cells for 1 hr. Cells were
then harvested and processed for analysis by flow cyto-
metry. Figure 2C shows that there was very little uptake
of peptides Phe-Oct6-FITC, Asn-Oct6-FITC, or Tyr-
Oct6-FITC up to 300 nM (geometric MFI increased
from approximately 40 to 100; the increase was not sig-
nificant by paired ANOVA). Coincubation of GLu-Oct6-
FITC with either carboxydansyl peptides Phe-Oct-Dan-
syl or Asn-Oct-Dansyl resulted in nearly unaltered
uptake of peptide Glu-Oct6-FITC without concomitant
uptake of either Phe-Oct6-Dansyl or Asn-Oct6-Dansyl
(Figure 2D). Because labeling the Phe-Oct6 peptide with
either FITC or dansyl resulted in peptides that had cyto-
toxicity at high concentrations (300 and 1000 nM; data
not shown), the experiment was performed again using
unlabeled Phe-Oct6 peptide in the presence of FITC-
labeled Glu-Oct6-FITC, to see if Phe-Oct6 could com-
pete with Glu-Oct6-FITC for binding and uptake. The
results shown in Figure 2E reveal that incubating cells
with Phe-Oct6 in the presence of Glu-Oct6-FITC did
not affect uptake of Glu-Oct6-FITC. All these data
taken together demonstrate that substituting Asn, Phe,
or Tyr for Glu did not interfere with uptake of Glu-
Oct6-FITC, indicating that uptake of Glu-Oct6-FITC
had some specificity requirement for Glu on the peptide.
To check for cytotoxicity in the unlabeled Phe-Oct6
and Glu-Oct6 peptides, these peptides were incubated
with PANC-1 and DU-145 cells for 18 and 48 hrs. At
the appropriate times, cells were harvested and stained
with FITC-labeled annexin V plus PI and analyzed by
Table 1 Peptides and Peptide-PNAs Included in Studies
Description Sequence Molecular Weight
Glu-FITC EEE-FITC 776 Da
Glu-Ala-FITC EEEAA-FITC 919 Da
Glu-Lys-FITC EEEAAKKK-FITC 1303 Da
Glu-Oct6-FITC EEEAAGRKRKKRT-FITC 1930 Da
Oct6- FITC GRKRKKRT-FITC 1400 Da
Phe-Oct6-FITC FFFAAGRKRKKRT-FITC 1984 Da
Asn-Oct6-FITC NNNAAGRKRKKRT-FITC 1885 Da
Phe-Oct6-dansyl FFFAAGRKRKKRT-dansyl 1875 Da
Asn-Oct6-dansyl NNNAAGRKRKKRT-dansyl 2058 Da
Glu-Oct6 EEEAAGRKRKKRT 1559 Da
Phe-Oct6 FFFAAGRKRKKRT 1613 Da
Tyr-Oct6 YYYAAGRKRKKRT 1661 Da







Carboxyfluorescein and carboxydansyl peptides were synthesized by FMoc
chemistry at the Molecular Resources Facility, UMDNJ. They were purified by
HPLC and sequence verified by the same technique. Carboxydansyl peptides
are synthesized using lysyl dansyl moieties. The peptide-PNAs were
synthesized by BioSynthesis; they were purified by HPLC and verified by
MALDI-TOF. The letters in bold indicate the PNA portions of the molecules.
The FITC moiety was coupled to Glu-Oct6-PNA as a lysyl-FITC, due to the
requirements of PNA chemistry.
Figure 1 Glu peptide or TAT was an inefficient CPP for PNA
uptake in DU-145 cells. DU-145 cells were incubated with 1000
nM FITC-PNA-EEE or FITC-PNA-TAT; at the indicated times cells were
harvested and analyzed by flow cytometry for FITC fluorescence.
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flow cytometry, in order to assess induction of apopto-
sis. Cell line viabilities at the start of the experiments
was 98% (determined by fluorescein diacetate staining
and microscopy); after treatment with Phe-Oct6 or Glu-
Oct6 peptides, cell viabilities were observed to be 97 to
100% (Table 2), indicating that the cytotoxicities seen
with the FITC- or dansyl-labeled Phe-Oct6 peptides
were not due to the peptide part of those molecules, but
rather due to the combination of the peptide plus the
fluorochromes (perhaps due to the high hydrophobicity
of those particular peptides). The conclusion from this
series of experiments is that Glu-Oct6 and Phe-Oct6
peptides in and of themselves are not cytotoxic and do
not induce apoptosis. The results of the experiments
presented in this subsection are evidence that uptake is
specific to the sequence of the Glu-Oct6 peptide.
Figure 2 Peptide uptake by prostate cancer cell lines. Figure 2A: Enhancement of Oct6 NLS peptide uptake by addition of Glu-Ala peptide
EEEAA on the N terminus. DU-145 cells were incubated with 500 nM peptides for 4 hours in Materials and Methods. Harvested washed cells
were subjected to flow cytometry on a FACScan. Dead cells were excluded by gating on 7-AAD-negative cells. * = geometric MFI of Glu-Lys-
FITC or Glu-Oct6-FITC was significantly greater than Glu-FITC (p < 0.01) or 356 (p < 0.05) by paired ANOVA. The average of 3 replicate
experiments is shown. Figure 2B: Effect of concentration on uptake of Glu-Oct6-FITC by DU-145, LNCaP and PANC-1 cells. Concentrations of
Glu-Oct6-FITC ranging from 0 to 300 nM were incubated with cells for 1 hr, at which time cells were harvested, washed, and processed for flow
cytometry. Figure 2C: Effect of substituting Phe, Asn, or Tyr for Glu on Oct6 NLS peptide uptake by DU-145 and PANC-1 cells. Cells were
incubated with 0 to 1000 nM of peptides for 1 hr at 37°C, then were harvested, washed, counterstained, and analyzed by flow cytometry to
quantify fluorescence. The average of 3 independent experiments ± SD is shown. Figure 2D: Lack of competition by Phe-Oct6-Dansyl or Asn-
Oct6-Dansyl on Glu-Oct6-FITC uptake by DU-145 cells. 300 nM of either Phe-Oct6-Dansyl or Asn-Oct6-Dansyl were incubated with 300 nM Glu-
Oct6-FITC for 1 hr, at which time cells were harvested, washed, and analyzed on a BD LSR II for dansyl and FITC fluorescence. CellQuest Pro was
used to analyze the fluorescence data. Turquoise line indicates dansyl fluorescence intensity; green line indicates fluorescein fluorescence
intensity. Figure 2E: Effect of 250-1000 nM Phe-Oct6 on 500 nM Glu-Oct6-FITC. DU-145 cells were incubated with peptides as before for 4 hrs;
cells were harvested, washed, fixed, then analyzed for fluorescence by flow cytometry. Green = no peptide; pink = Glu-Oct6-FITC alone; blue =
Glu-Oct6-FITC + 250 nM Phe-Oct6; red = Glu-Oct6-FITC + 500 nM Phe-Oct6; purple = Glu-Oct6-FITC + 1000 nM Phe-Oct6.
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Uptake of all peptides was temperature-dependent, but
uptake of peptides containing the Oct6 NLS only was
inhibited by NaN3
In order to determine if peptides entered cells by diffusion
or by an ATP-dependent process, the following experi-
ments were performed. First, uptake of 300 nM peptides
Glu-FITC, Glu-Ala-FITC, Glu-Lys-FITC, Glu-Oct6-FITC,
and Oct6-FITC was compared at 4, 23, and 37°C for 4 hr
in DU-145 cells. As shown in Figure 3, uptake of peptides
tested was temperature-dependent, with best uptake
observed at 37°C. Even at 4°C, peptides Glu-Oct6-FITC
and Oct6-FITC exhibited greatly enhanced uptake, com-
pared with the other peptides (average geometric MFIs
were 486 for Glu-Oct6-FITC and 325 for Oct6-FITC,
compared with average geometric MFI of 186 for Glu-Lys-
FITC and geometric MFIs that were less than 100 for Glu-
FITC and Glu-Ala-FITC). In the case of PANC-1 cells, a
similar pattern of temperature dependence of uptake was
observed. At 4°C, the average geometric MFIs for all pep-
tides were found to be 50 to 110 (Figure 3); at 25°C the
average geometric MFIs increased again increased slightly
for Glu-FITC (to about 60) and Glu-Ala-FITC (to about
70). However, the average geometric MFI of Glu-Lys-
FITC increased to about 150, that of Glu-Oct6 to about
175, and the average geometric MFI of Oct6-FITC was
about 225. At 37°C, the average geometric MFIs of the
Glu-FITC and Glu-Ala-FITC peptides were still less than
100 (about 70 and 80, respectively), whereas the average
geometric MFI of the peptides containing the NLS either
remained constant (Oct6-FITC), increased to over 200
(Glu-Oct6-FITC), or decreased (Glu-Lys-FITC). These
data confirm the temperature-dependent uptake of Oct6
NLS-containing peptides in PANC-1 cells.
Usually, marked temperature dependence such as
observed for these peptides is indicative of uptake by
endoctytosis [15]. If this is the case, then uptake would
be expected to be inhibited by depletion of ATP. To
investigate this, experiments were performed for 4 hr at
37°C in the presence of NaN3. Table 3 shows that the
addition of up to 1% NaN3 to DU-145 cells had little
effect on the uptake of peptides Glu-FITC, Glu-Ala-
FITC, or Glu-Lys-FITC at 300 nM (addition of 1%
NaN3 inhibited the uptake of these peptides by less than
25%). However, the geometric MFI of 300 nM peptide
Oct6-FITC was reduced from nearly 418 to 181 in the
presence of 1% NaN3, while the geometric MFI of pep-
tide Glu-Oct6-FITC was decreased from 151 to 114 in
the presence of 1% NaN3. The addition of as little as
0.1% NaN3 inhibited the average geometric MFI for
Oct6-FITC, reducing it from 418 to 293 (Table 3).
These data indicate that uptake of the smaller peptides
was ATP-independent but that uptake of the larger pep-
tides containing the Oct6 NLS was ATP-dependent.
Uptake of peptides lacking the Oct6 NLS was observed
to be temperature-dependent but uptake was unaffected
by up to 1% NaN3; on the other hand uptake of peptides
Glu-Oct6-FITC and Oct6-FITC, both of which contain
the Oct6 NLS, was inhibited by 1% NaN3 by over 50%
(Tables 2 and 3). These preliminary studies demon-
strated that uptake of peptides lacking the Oct6 NLS is
likely through a non-endocytic mechanism and is not
receptor-mediated whereas uptake of peptide containing
the Oct6 NLS proceed through a different mechanism,
but more studies have to be conducted to confirm if
this observation is generalizable to other NLS peptides.
Peptide Glu-Oct6-FITC colocalized to the nucleus
Since flow cytometry only gives data regarding total
shifts in fluorescence of a population, imaging flow cyto-
metry and live imaging microscopy studies were per-
formed to determine if the NLS augmented nuclear
accumulation of the peptides. Imaging flow cytometry
was chosen to provide data on intracellular distribution
of FITC-labeled peptides. Inverted epifluorescence
microscopy was chosen to eliminate inadvertant artifacts
that may arise from fixation, such as nuclear transloca-
tion [16]. For these studies, the cell-permeable fluoro-
chrome DRAQ5 was used because it readily enters and
stains nuclei of viable cells [17]. Imaging flow cytometry
revealed that peptide Glu-Oct6-FITC accumulated in
the nucleus of DU-145 and LNCaP cells much better
than did peptide Glu-Ala-FITC; at 250 nM Glu-Oct6-
FITC was distributed approximately 50% in the nucleus
and 50% in the cytoplasm. It was not retained in the
plasma membrane (Figure 4A). In contrast, peptide Glu-
Ala-FITC showed much less accumulation in the cells
when the plasma membrane was excluded from the
Table 2 Cell Viability after Incubation with Peptides Glu-
Oct6 and Phe-Oct6
Cell Line Peptide Concentration, nM % Viability












DU-145 and PANC-1 cells were incubated with 300 - 1000 nM peptides for 4
hr, then harvested, stained with FITC-annexin V/PI, washed and analyzed by
flow cytometry to determine the cell viability using a FACScan flow cytometer
and CellQuest Pro software. The average of 3 replicate experiments is shown.
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analysis. To be certain these results were not due to
artifactual translocation due to fixation, live cell imaging
studies were performed. We observed that 500 nM of
peptide Glu-Oct6-FITC, but not peptides Glu-FITC,
Glu-Ala-FITC, or Oct6-FITC, accumulated in the nuclei
of DU-145 and LNCaP cells after 24 hrs incubation
(Figure 4B-D). The translocation of peptides to nuclei
was complete in the sense that FITC and DRAQ5 fluor-
escence colocalized in all viable cells, although cytop-
lasmic fluorescence was visible as well. The FITC
distribution was somewhat punctate in the cytoplasmic
portion of cells, leading us to conclude that the peptide
may be accumulating within endosomes. These studies
show that the presence of the glutamate-rich peptide
EEEAA on the N-terminus of the Oct6 NLS of peptide
Glu-Oct6-FITC enhanced nuclear colocalization as well
as uptake.
Peptide Glu-Oct6 facilitated transport of a synthetic
oligonucleotide into prostatic and pancreatic cancer
cell lines
Because the ultimate goal of these studies is to use pep-
tide Glu-Oct6 to ferry in a therapeutic cargo, the hybrid
molecule Glu-Oct6-PNA was synthesized, which con-
sisted of Glu-Oct6 at the N terminus and the carboxy-
fluorescein peptide nucleic acid (PNA) having the inert
sequence TATGATCTCCTCCGT-lysyl-FITC at the C
terminus (Glu-Oct6-PNA-FITC). Glu-Oct6-PNA-FITC
was incubated with DU-145 and PANC-1 cells at 0, 300,
and 1000 nM for 18 hr, at which time cells were har-
vested and processed for flow cytometry. Figure 5 shows
that increasing the concentration of Glu-Oct6-PNA-
FITC increased the MFI of the cells, and the percent of
cells positive for FITC fluorescence. Analysis of PANC-1
cells by imaging flow cytometry, which can quantify colo-
calization of fluorescent dyes to subcellular organelles
[18] revealed that Glu-Oct6-PNA-FITC colocalized to a
great extent with the nuclear stain DRAQ5 (Figure 5A).
IDEAS software analysis of the 4 to 5 thousand cellular
events acquired revealed that the extent of colocalization
Figure 3 Effect of temperature on peptide uptake. Carboxyfluorescein-labeled peptides were incubated with DU-145 and PANC-1 cells at 300
nM over 4 hours at 4, 25, at 37°C. Harvested washed cells were analyzed on a FACScan flow cytometer. The results of representative experiments
are shown.
Table 3 Sodium Azide Inhibited Uptake of Peptides with
Oct6 NLS
Peptide NaN3, % Avg Geometric MFI % Inhibition
Glu-FITC 0 25.6 0
0.1 26.4 0
1.0 29.7 0
Glu-Ala-FITC 0 43.8 0
0.1 56.9 0
1.0 48.4 0
Glu-Lys-FITC 0 58.6 0
0.1 61.8 0
1.0 47.4 19.1
Glu-Oct6–FITC 0 151.4 0
0.1 155.7 0
1.0 114.4 24.8
Oct6-FITC 0 417.6 0
0.1 293 29.8
1.0 181 56.7
DU-145 cells were incubated with 300 nM peptides for 4 hr in the presence or
absence of NaN3. Cells were washed and analyzed by flow cytometry to
determine the geometric mean fluorescence intensities using a FACScan flow
cytometer and CellQuest Pro software. The average of 3 replicate experiments
is shown.
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was approximately 70% nucleus and 20% cytoplasmic
across all events examined (Table 4). The fluorescent
intensities for PNA-FITC in nuclei of both cell lines was
much greater than those measured in the cytoplasmic
portions (Table 4), indicating that the PNA accumulated
in the nuclei to a much greater extent than in the cyto-
plasm. The percents do not add up to 100% because they
exclude the portion that localized to the cell membrane
asa well as whatever amount of PNA clung to cellular
debris. In addition, a small but highly fluorescent popula-
tion of cells (having a MFI greater than 103) was appar-
ent, even as low as 300 nM (Figure 5B). Furthermore,
PANC-1 cells increased in proportion of FITC positive
with increasing concentration of Glu-Oct6-PNA-FITC
(Figure 5C). Therefore, conjugating Glu-Oct6 peptide to
a PNA facilitated entry and nuclear colocalization of the
PNA into both DU-145 and PANC-1 cell lines.
Peptide Glu-Oct6 facilitated transport of an anti-STAT3
PNA into cancer cell lines, resulting in apoptosis
To determine if the creation of an anti-STAT3 PNA
that is transported into cells by the novel CPP Glu-Oct6
is feasible, a PNA was synthesized bearing Glu-Oct6 on
the N terminal portion, plus an anti-STAT3 sequence,
13410a [2]. A control PNA consisted of the 13410a
sequence without a peptide coupled to it. These were
incubated with DU-145 or PANC-1 cells for48hr, at
which times cells were harvested, stained, and analyzed
by flow cytometry to quantify apoptosis. Table 5 shows
that significant apoptosis was induced in both DU-145
and PANC-1 cells by as little as 600 nM Glu-Oct6-
13410a (48 and 69% respectively; p < 0.01 by repeated
ANOVA; Table 5), whereas addition of PNA 13410a,
lacking any CPP, induced very little apoptosis at 1000
nM (1% or less; Table 5). These data are encouraging
Figure 4 Imaging studies. Figure 4A: DU-145 and LNCaP cells were incubated with 250 nM Glu-Ala-FITC or Glu-Oct6-FITC for 4 hours,
counterstained with 5 mM DRAQ 5, then fixed in paraformaldehyde and analyzed by imaging flow cytometry on an Amnis Imaging Cytometer.
IDEAS software (Amnis) was used to generate and colorize the images. Across each row of images, one is viewing the same cell under different
fluorescence excitations. Thus for each cell type and peptide, the left-most column shows the merged images, the middle column shows the
DRAQ5 images, and the right-most column shows the FITC images (labeled below each set of 3 channels as m for merge, D for DRAQ5, and F
for FITC). Analysis using IDEAS software revealed that Glu-Oct6-FITC distributed about 50% in nuclei and 50% in cytoplasm of cells, whereas only
~10% of nuclei were positive for DRAQ5 and FITC colocalization in the case of Glu-Ala-FITC. Figure 4B: Live cell imaging of Glu-Oct6-FITC by
DU-145 cells. 500 nM Glu-Oct6-FITC was incubated with DU-145 cells overnight (necessary for imaging purposes). Cells were washed with
phenol red-free buffer, counter-stained with DRAQ5 at 10 mM, and then examined under a Zeiss Axiovert 200 inverted phase contrast
microscope with epifluorescence. The merged image confirms the presence of Glu-Oct6-FITC in nuclei. Merged images with and without
Nomarski interference are shown. Figure 4C and D: DU-145 cells incubated with Glu-FITC and Oct6-FITC, as described for Figure 3B. Note the
absence of FITC fluorescence in nuclei. Figure 3D merged image shows the Nomarski interference image overlayed on the fluorescence images.
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for the future development of experimental therapeutics
using Glu peptides bound to transcription factor NLS
peptides for aiding the translocation of active payloads
into cells. Further work in this area of peptide design is
planned.
Discussion
The use of NLS peptides was explored because of their
potential to ferry therapeutic cargoes efficiently. Pre-
viously, it was observed that the Oct6 NLS peptide
accumulated in the endosomal compartments of cells
[13]. However, it was observed that addition of peptide
EEEAA to the N-terminus of the Oct6 NLS enhanced
cellular uptake and also enhanced nuclear localization.
The AA residues were added so that the Glu peptide
would be spatially separated from the NLS portion, to
maximize binding of each. Ala-rich linker peptides
have been described before to link functional domains
of various proteins [19]. It was further observed that
although Glu-Oct6 facilitated entry of a PNA into DU-
Figure 5 Glu-Oct6 facilitated entry of a PNA into DU-145 and PANC-1 cells. Glu-Oct6-PNA-FITC (0 to 1000 nM) was incubated with DU-145
or PANC-1 cells for 18 hr, at which time cells were harvested, washed, and processed for flow cytometry or imaging cytometry as described
previously. Figure A: PANC-1 cells incubated with Glu-Oct6-PNA-FITC. IDEAS software (Amnis) was used to generate and colorize the images.
Across each row of images, one is viewing the same cell under different fluorescence excitations. Thus for each cell type and peptide, the right-
most column shows the merged images, the middle column shows the DRAQ5 images, and the left-most column shows the FITC images. Four
thousand cells total were analyzed. Figure B: Uptake of Glu-Oct6-PNA-FITC by DU-145 cells quantified by flow cytometry. Figure C:
Concentration-dependent increase in FITC fluorescence by PANC-1 cells incubated with Glu-Oct6-PNA-FITC, assessed by flow cytometry.
Table 4 Glu-Oct6 Facilitated Nuclear Colocalization of PNA 13778a
Cell line mean % nuclear FITC mean nuclear FITC intensity mean % cyto. FITC mean cyto. FITC intensity
DU-145 68.04 274,597 22.48 76,943
PANC-1 72.61 322,794 21.8 68,465
Cells were incubated with 1000 nM Glu-Oct6-PNA-FITC for 18 hr, at which time cells were fixed with 4% paraformaldehyde, stained with 5 μM DRAQ5 for nuclear
localization, and analyzed on an Amnis ImageStream imaging cytometer.
Four to 5 thousand events were collected and analyzed using IDEAS software (Amnis).
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145 cells, higher concentrations and longer incubation
times were required for the PNA than for the peptide
Glu-Oct6-FITC. It is conceivable that there is a large
energy barrier to overcome for efficient transport of
PNA into cells, despite their neutral charge and despite
the apparently enhanced cell uptake properties of Glu-
Oct6 ([20] and Figures). It is entirely possible that
Glu-Oct6 would function as a more efficient CPP if
the form of the therapeutic payload were changed
from a PNA to a different entity, such as a locked
nucleic acid. Notwithstanding, Glu-Oct6 deserves
further study as a potential probe for studying nuclear
localization events, and as a CPP for ferrying other
forms of therapeutic payloads, such as peptides or
liposomes.
Temperature-dependence of peptide uptake has been
found to correlate as well with segregation to intracellu-
lar compartments. Fretz and coworkers observed that at
lower temperatures (4 to 12°C), L- and D-octa-arginine
peptides partitioned across nuclear and cytoplasmic
compartments equally, moving to the endosomes of
CD34+ leukemia cells when ambient temperature rose
to 30°C and higher [21]. They further observed that rais-
ing concentration affected which intracellular compart-
ments were labeled by peptides [21]. Similarly,
temperature-dependent uptake of peptide Glu-Oct6-
FITC (Figure 3) was observed in DU-145 and PANC-1
cell lines; furthermore Glu-Oct6-FITC partitioned across
nuclei and cytoplasm (Figure 4A and 4B), whereas
neither peptides Glu-FITC nor Oct6-FITC exhibited
appreciable nuclear localization (Figure 4C and 4D). The
Oct6 transcription factor is known to shuttle between
cytoplasm and nucleus [22]; this would be expected of
transcription factors. However, the NLS peptide of a
transcription would not be expected to shuttle, since it
is not activated. Rather, one might expect that an NLS
peptide accumulates in one or more select organelles.
Indeed, Ragin and coworkers observed such accumula-
tion with regard to the Oct6 NLS and others [13]; accu-
mulation across cytoplasm and nucleus by Glu-Oct6-
FITC indicates that addition of the Glu-rich peptide to
the Oct6 NLS prevents the endoplasmic sequestration
by a mechanism that has yet to be explored. Several
mechanisms of peptide uptake are known; ATP-depen-
dent and ATP-independent peptide uptake are two
major differentiating features of peptide uptake but by
no means the only ones. Even within the same cell line,
investigators have observed multiple modes of peptide
uptake; endocytic and non-endocytic modes of uptake
were noted in the V79 and PC12 cell lines [23]. Further-
more, the uptake of NLS peptides by the MCF-7 breast
cancer cell line was found to be temperature-dependent
but unaffected by the presence of NaN3 [13].
PNAs have been a focus of cancer researchers for over
a decade. Early work on PNAs for cancer therapy
showed that anti-sense PNAs directed against the
androgen receptor and TATA-binding protein genes
worked by hybridization with CAG triplet repeats in
LNCaP and DU-145 cell lines; no binding to c-myc,
which lacks the CAG repeats was observed [24].
Although marked effects on the transcriptosomes of the
androgen receptor and TATA-binding proteins genes
were observed, the PNAs were not designed to be thera-
peutically active. Elegant studies on T47D and MCF-7
breast cancer cell lines with PNA-peptide conjugates
targeting human progesterone receptor gene isoforms A
and B revealed the extent to which expression of pro-
gesterone receptor protein was attenuated [25]. More
recently, investigators showed therapeutic efficacy in a
mouse model of Burkitt’s lymphoma using an anti-sense
PNA targeted to the Em enhancer region of the H chain
locus, which in Burkitt’s lymphoma is transposed near
the c-myc locus [26].
Glutamate receptors are known to be overexpressed by
cancer cells. In prostate cancer, the best known is PSMA,
which binds carboxy glutamates [27,28]. PSMA we believe
is not involved because DU-145 cells are PSMA-negative
[29], and because the glutamate is on N-termini of the
peptides. Metabotropic glutamate receptors are usually
found on neuronal cells but are found to be aberrantly
expressed by malignant cells. These glutamate receptors
mediated 5-fluorouracil resistance in human colon cancer
cells [30]. Glutamate receptors are implicated in transfor-
mation to malignancy; it’s hypothesized that glutamate
receptors overexpression may be a common feature of
tumor pathogenesis. Thus glutamate receptors may be
typical of what Glu-Oct6 binds to on DU-145, LNCaP,
and PANC-1 cells. The activity of normal glutamate recep-
tors in ectopic cellular environments may involve signaling
pathways, which dysregulate cell growth, ultimately lead-
ing to tumorigenesis. Thus, dysregulated and aberrantly-
Table 5 PNA Glu-Oct6-13410a Induced Apoptosis in DU-
145 and PANC-1 Cells
DU-145
nM PNA 0 300 600 1000 13410a
% apop. 0.05 8.7 48.7* 82.5* 2.9
SD 0.04 7.7 24.1 5.9 4.6
PANC-1
nM PNA 0 300 600 1000 13410a
% apop. 0.3 17.4 69.6* 84.6* 1.1
SD 0.2 14.6 5.9 14.6 0.8
Cells were incubated with PNAs Glu-Oct6-13410a or 13410a for 48 hr, at
which time they were harvested and stained with FITC-annexin V plus PI, then
apoptosis was quantified by flow cytometry. PNA 13410a was added at 1000
nM. The percents apoptosis are the means of 3 experiments; SD = standard
deviation.
* p < 0.01 by repeated ANOVA
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expressed glutamate receptors may function as oncogenes
[31]. Malignant prostatic neuroendocrine cells proliferate
more when glutamate receptors are stimulated; they use
glutamate as a substrate for NADH biosynthesis, produ-
cing increased levels of free fatty acids. These activities
correlate with the aggressive nature of these tumors [32].
Glutamate receptors have been understudied and certainly
have not yet been widely used for cancer-specific targeting.
Since glutamate receptors are overexpressed on a variety
of solid tumors [31], they should lend themselves well to
cancer cell targeting by a variety of strategies, including
CPP design. This should be the focus of future work.
Recent papers on peptide uptake indicates that nuclear
colocalization, even by transcription factor NLS pep-
tides, is not easily achieved [13]. Here we describe the
enhancement of uptake and nuclear localization of a
NLS through addition of a peptide. Whether addition of
the peptide enhances uptake and nuclear localization
when coupled to the NLS of other transcription factors
and whether the enhancement is sequence-specific is
under investigation.
Conclusions
The use of the Oct6 NLS peptide as a CPP was
explored. Peptide Glu-Oct6-FITC was shown to gain
entry into DU-145, PANC-1, and LNCaP cells quickly
and efficiently, and localized to the nucleus. Its ability to
function as a CPP was concentration- and temperature-
dependent, and abrogated in the presence of azide. The
homologous peptide Oct6-FITC, which consisted of the
Oct6 NLS peptide alone and lacked the N-terminal glu-
tamate-rich peptide, did not localize to the nucleus. The
ability of Glu-Oct6 to function as a CPP was lost when
Phe, Tyr, or Asn were substituted for the Glu residues.
Peptide Glu-Oct6 facilitated entry of a carboxylysyl-
fluorescein PNA into DU-145 and PANC-1 cells. Finally,
peptide Glu-Oct6 facilitated transport of an anti-STAT3
PNA into DU-145 and PANC-1 cells, resulting in signif-
icant apoptosis. Therefore, Glu-Oct6 may be a peptide
useful for therapeutic applications.
Methods
Synthesis of Peptides and Peptide-PNA
Peptides used are listed in Table 1 and are referred to by
their synthesis numbers for convenience. The carboxy-
fluorescein and carboxydansyl amino acids were pur-
chased from Bachem. All peptides used had a molar ratio
of FITC or dansyl to peptide of 1. All peptides were
synthesized by the Molecular Resources Facility at the
University of Medicine and Dentistry, New Jersey Medi-
cal School (Newark, NJ) on an Applied Biosystems model
433 peptide synthesizer using FMoc chemistry. After
cleavage and deprotection, the peptides were purified by
high-performance liquid chromatography (HPLC) and
analyzed by both HPLC and sequencing on an Applied
Biosystems Procise 494C sequenator. The FITC-labeled
peptide-PNAs FITC-PNA-EEE, FITC-TAT-PNA, and
Glu-Oct6-PNA-FITC were synthesized by BioSynthesis
(Lewisville, TX). They were purified by HPLC and their
structures verified by MALDI-TOF. Because of the
requirements of PNA chemistry, FITC was added to the
C-terminus of Glu-Oct6-PNA as lysyl FITC.
Cells
DU-145 and LNCaP cells were the gift of Dr. James
Turkson (University of Central Florida, Orlando, FL).
DU-145 cells were grown in DMEM/Ham’s F12 (Invi-
trogen, Carlsbad, CA) plus 10% newborn bovine serum
(Hyclone, Logan, UT). LNCaP cells were maintained in
RPMI-1640 (Invitrogen) plus fetal bovine serum
(Hyclone). PANC-1 cells were the gift of Dr. James Free-
man, University of Texas Health Sciences Center, San
Antonio TX. They were grown in the same medium as
the DU-145 cells. Cell viabilities were determined using
fluorescein diacetate (Sigma Chemical Co., St. Louis,
MO) and a Universal RIII fluorescence microscope
(Zeiss, Jena, Germany).
Uptake/Fluorescence Quantification and Nuclear
Colocalization Studies
Peptides were added to subconfluent cultures of cells at
times, temperatures, and concentrations indicated in
experiments. Concentrations ranging from 0 to 1000 nM
were assayed. Fluorescence was normalized using calibra-
tion beads (Becton-Dickinson; BD). Cells were analyzed
in the presence of 5 mM 7-AAD (eBioscience, San Digeo
CA) to gate on live events. Fluorescence was quantified,
after cells were harvested, using a BD FACScan flow cyt-
ometer. At least 10,000 events were acquired using Cell-
Quest Pro software and an Apple Macintosh G4 dual
coprocessor computer running OS X 10.3.9. Fluorescence
detectors on the instrument were standardized prior to
each acquisition run, so that fluorescence intensities from
different days could be compared. Because the FACScan
employs logarithmic amplifiers on the fluorescence detec-
tors, the more accurate parameter with which to compare
fluorescence intensities for different samples is the geo-
metric mean fluorescence intensity (geometric MFI). For
the studies examining uptake of carboxyfluorescein pep-
tides plus carboxydansyl peptides, fluorescence was quan-
tified on a BD LSR II flow cytometer. In nuclear
colocalization studies, cells were stained with the nuclear
stain DRAQ5 (Axxora, San Diego, CA) at 5 mM final
concentration following uptake of peptides. Fixed cells
(4% paraformaldehyde/DPBS) were then analyzed on an
Amnis ImageStream 200 imaging cytometer using IDEAS
3.0 software. Four to five thousand events were collected
for analysis.
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Live Cell Imaging Studies
A Zeiss Axiovert 200 inverted phase-contrast micro-
scope outfitted with epifluorescence was used for live
imaging studies. Subconfluent cultures of cells in 12-
well plates were incubated with 500 nM peptides as
indicated. DRAQ5 (Axxora; 10 mM final concentration)
was added for the last hour of incubation, then the cells
were washed twice with warm phenol red-free buffer.
Cells were examined in phenol red-free buffer plus 10%
serum. Images were acquired and analyzed using Zeiss
Axiovision software.
Apoptosis Studies
DU-145 and PANC-1 cells were incubated with PNAs
Glu-Oct6-13410a or 13410a (no CPP attached) at 0,
300, 600, or 1000 nM for 48 hr. Cells were harvested,
then stained with FITC-annexin V (Abcam; Cambridge,
MA) and counterstained with propidium iodide (Sigma,
St.Louis, MO). Cells were analyzed on a BD FACScan
for fluorescence in the FL1 and FL3 channels; CellQuest
Pro software was used to quantify fluorescence and
determine the extent of apoptosis.
Statistical Analysis
The graphing program Kaleidagraph 4.2 (Synergy Soft-
ware, Reading, PA) and the statistical program InStat3
(GraphPad Software, San Diego, CA) were used for data
analyses unless otherwise indicated.
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